Welcome to Action Kidney Cancer

The United Kingdom’s only patient-led kidney cancer charity

Steve shares his experience of living with kidney cancer

Join our patient support forum for friendly patient-to-patient support and advice

Learn about Action Kidney Cancer’s patient services

Newly diagnosed with kidney cancer

Kidney cancer treatments

Fundraising

Patient Support Forum

Stronger together

In our own words

During this series of videos, kidney cancer patients and carers talk frankly about their experiences, emotions and how to live well with a diagnosis of kidney cancer
Coping with a diagnosis of kidney cancer
Talking about kidney cancer
A carer’s perspective

Real stories

The lives of all these people have been affected by kidney cancer
Some are patients, some are carers, all are stories by real people sharing their experiences of living with kidney cancer

Latest kidney cancer news

17 Apr 2024

Cancer52 manifesto launch

Read More

12 Apr 2024

Immunotherapy combinations versus TKIs for papillary renal cell carcinoma

Read More

9 Apr 2024

CAR T cell immunotherapy shows promise for patients with kidney cancer

Read More

9 Apr 2024

Real world data on the use of cabozantinib plus immunotherapy in the second line

Read More

25 Mar 2024

How to manage anxiety and depression when you have kidney cancer

Read More

12 Mar 2024

Immunotherapy improves survival in kidney cancer patients with brain metastases

Read More

8 Mar 2024

Radiotherapy for the management of renal medullary carcinoma

Read More

8 Mar 2024

Manchester patient focus group

Read More

8 Mar 2024

NICE approves cabozantinib plus nivolumab for advanced kidney cancer

Read More

15 Feb 2024

PRISM study highlights possibility of reducing dose of immunotherapy

Read More

15 Feb 2024

World-class radiotherapy in the UK

Read More

7 Feb 2024

Summary of kidney cancer highlights from ASCO GU 2024

Read More

Action Kidney Cancer

Friendship...community...encouragement...advocacy...information...support...kindness...advice...shared experiences...patient stories...research news...expert insights...empowerment...
Action Kidney Cancer
Action Kidney Cancer15 hours ago
Yesterday (16 April 2024) Cancer52 launched 'The Other Half. A manifesto to transform outcomes for people with rare and less common cancers'. The event was hosted by Will Quince MP at the House of Commons, Westminster. Action Kidney Cancer was represented at the event by Sharon Deveson Kell.

Read the manifesto on our website here:
Action Kidney Cancer
Cancer52 manifesto launch
Yesterday (16 April 2024) Cancer52, an alliance of over 100 charities representing rare and less common cancers, launched The Other Half. A manifesto to transform outcomes for people with rare and less common cancers. The event was hosted by Will Quince MP at the House of Commons, Westminster. Actio...
View on Facebook
Action Kidney Cancer
Action Kidney Cancer15 hours ago
We have just added two new videos to our ask Ask the expert videos. In this series of videos, experts in the treatment and care of kidney cancer patients answer your questions.

The two new videos are Clinical Trials Part -I and Clinical Trials- Part 2.

In these videos Sharon Devenson Kell interviews Professor Grant Stewart, a urological surgeon from Addenbrookes Hospital, Cambridge, about why new treatments are tested, what is a clinical trial and why are they run, what are the different phases of clinical trials, why are people with rare subtypes of kidney cancer, brain metastases or other conditions/diseases excluded from trials, and publishing of negative clinical trials.

Sharon in Part-2 asks Grant about involvement of patients and the public in the design of clinical trials, trials to compare treatments, and why there are not more hospitals running clinical trials in the UK.

To watch these videos please follow the link below:

https://actionkidneycancer.org/help-support/ask-the-expert/

#kidneycancer #bypatientsforpatients #StrongerTogether
Action Kidney Cancer
');jQuery( ".feed_dynamic_video_classseqaurxrvk_page .fts-greater-than-width-height.fts-fb-video-on-page, .feed_dynamic_video_classseqaurxrvk_page iframe" ).css({"height": "405px", "width": "720px"});});});
View on Facebook
Action Kidney Cancer
Action Kidney Cancer2 days ago
In this last week we have been very busy representing kidney cancer patients at a variety of different events. We attended the seventh annual International Kidney Cancer Conference in Seoul Korea.

Steve Pointon one of our colleagues was one of the guest speakers at the event, sharing his experience of living with kidney cancer.

#kidneycancer #bypatientsforpatients #StrongerTogether
Action Kidney Cancer
View on Facebook
Action Kidney Cancer
Action Kidney Cancer2 days ago
Today we are in London representing the voice of kidney cancer patients and supporting the launch of Cancer52’s Manifesto for rare and less common cancers, and its three key asks: To reduce mortality and health inequalities, increase early diagnosis, and put patients at the core of a new nation mission on rare and less common cancers.

#kidneycancer #bypatientsforpatients #StrongerTogether #c52manifesto
Action Kidney Cancer
+1
View on Facebook
Action Kidney Cancer
Action Kidney Cancer6 days ago
Papillary renal cell carcinoma (pRCC) is the most common subtype of non-clear cell kidney cancer. People with papillary RCC are often excluded from large phase 3 trials, which focus on the more common form of kidney cancer, clear cell RCC. Therefore, treatment options for non-clear cell kidney cancers are limited. The aim of this study was to look at the effectiveness of immunotherapy combinations compared to TKIs for the treatment of previously untreated patients with papillary RCC.

Read more on our website here:
Action Kidney Cancer
Immunotherapy combinations versus TKIs for papillary renal cell carcinoma
Papillary renal cell carcinoma (pRCC) is the most common subtype of non-clear cell kidney cancer. People with papillary RCC are often excluded from large phase 3 trials, which focus on the more common form of kidney cancer, clear cell RCC. Therefore, treatment options for non-clear cell kidney cance...
1View on Facebook
Action Kidney Cancer
Action Kidney Cancer1 week ago
Chimeric antigen receptor (CAR) T cell therapy is a type of immunotherapy that changes T cells so they are able to recognise and attack cancer cells.

T cells are immune system cells that play several key roles in the body’s fight against disease. They help the immune system respond to disease and they attack and kill abnormal cells. Unfortunately, naturally occurring T cells in patients with cancer are not good at recognising and fighting cancer cells.

Results from a study in America have shown that more than 80% of patients with advanced kidney cancer benefited from CAR T cell therapy.

Read more on our website here:
Action Kidney Cancer
CAR T immunotherapy shows promise for patients with kidney cancer
Chimeric antigen receptor (CAR) T cell therapy is a type of immunotherapy that changes T cells so they are able to recognise and attack cancer cells. T cells are immune system cells that play several key roles in the body’s fight against disease. They help the immune system respond to disease and ...
1View on Facebook
[php_everywhere instance="3"]